Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M386Revenue $M50.2Net Margin (%)40.2Z-Score20.5
Enterprise Value $M256EPS $0.6Operating Margin %40.0F-Score5
P/E(ttm))134Cash Flow Per Share $-0.3Pre-tax Margin (%)40.2Higher ROA y-yY
Price/Book2.010-y EBITDA Growth Rate %0Quick Ratio17.5Cash flow > EarningsN
Price/Sales6.85-y EBITDA Growth Rate %0Current Ratio18.2Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)16.8Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)44.3Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M41.6ROI % (ttm)-150.9Gross Margin Increase y-yN

Gurus Latest Trades with VNDA

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VNDAJohn Paulson 2014-06-30 Add0.12%$9.7 - $16.96
($13.27)
$ 9.26-43%Add 129.80%3,200,000
VNDAJohn Paulson 2014-03-31 Buy 0.11%$10.5 - $18.71
($14.13)
$ 9.26-53%New holding1,392,500
VNDAJean-Marie Eveillard 2013-09-30 Sold Out -0.02%$8.05 - $13.031
($10.72)
$ 9.26-16%Sold Out0
VNDAJean-Marie Eveillard 2013-06-30 Reduce-0.01%$3.93 - $13
($6.73)
$ 9.2627%Reduce -48.99%975,000
VNDAJean-Marie Eveillard 2012-12-31 Add0.01%$3.03 - $4.16
($3.54)
$ 9.2662%Add 43.16%1,911,452
VNDAJean-Marie Eveillard 2010-03-31 Add0.04%$10.01 - $12.38
($10.94)
$ 9.26-18%Add 111.12%752,375
VNDAJean-Marie Eveillard 2009-12-31 Buy 0.04%$9.59 - $11.84
($10.79)
$ 9.26-17%New holding356,375
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VNDA is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


VNDA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Kelly James PatrickSVP, CFO, Sec & Treasurer 2015-03-10Sell12,450$10.53-12.06view
Polymeropoulos Mihael HristosPresident and CEO 2015-03-10Sell21,900$10.53-12.06view
Baroldi PaoloSVP & Chief Medical Officer 2015-03-10Sell8,940$10.54-12.14view
DUGAN RICHARD WDirector 2015-03-09Sell4,804$10.69-13.38view
Flynn James E 2014-12-23Buy162,014$14.4-35.69view
Watkins ThomasDirector 2014-03-14Sell35,000$17.66-47.57view
Repella RobertSVP & Chief Commercial Officer 2013-11-21Sell107,500$12.03-23.03view
Kelly James PatrickSVP, CFO, Sec & Treasurer 2013-11-19Sell3,348$12.07-23.28view
Polymeropoulos Mihael HristosPresident and CEO 2013-11-19Sell8,928$12.07-23.28view
Feeney John JosephSVP & Chief Medical Officer 2012-02-16Sell4,760$4.6599.14view

Press Releases about VNDA :

    Quarterly/Annual Reports about VNDA:

      News about VNDA:

      Articles On GuruFocus.com
      John Paulson's Stocks Trading for Less Than He Paid for Them Jun 02 2014 
      Best Performing Gurus of Past Six Months are John Paulson, First Eagle and Michael Price Jun 11 2013 
      comment on VNDA Nov 12 2012 
      Vanda: This Company Has Great Assets But No Profits Jan 21 2012 
      Vanda Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
      $VNDA New study started: Oct 15 2010 
      Hourly trend UP Aug 11 2010 
      Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
      upgraded to BUY Jul 07 2010 
      Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) May 10 2010 

      More From Other Websites
      Nasdaq stocks posting largest percentage decreases Mar 27 2015
      VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers Mar 20 2015
      VANDA PHARMACEUTICALS INC. Financials Mar 20 2015
      VANDA PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report Mar 13 2015
      Vanda Down after Candidate Disappoints in Phase II Study - Analyst Blog Mar 09 2015
      Vanda's eczema drug fails mid-stage study, shares fall Mar 04 2015
      VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 04 2015
      Vanda's eczema drug fails mid-stage study Mar 04 2015
      Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic... Mar 04 2015
      Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic... Mar 04 2015
      Vanda Pharmaceuticals Inc Earnings Call scheduled for 10:00 am ET today Feb 19 2015
      Vanda posts 4Q profit Feb 19 2015
      Vanda posts 4Q profit Feb 19 2015
      Vanda Pharmaceuticals Reports Fourth Quarter 2014 and Full Year 2014 Financial Results Feb 19 2015
      Q4 2014 Vanda Pharmaceuticals Inc Earnings Release - Before Market Open Feb 19 2015
      VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 19 2015
      Vanda Pharmaceuticals Reports Fourth Quarter 2014 and Full Year 2014 Financial Results Feb 19 2015
      Vanda Pharmaceuticals to Announce Fourth Quarter 2014 Financial Results on February 19, 2015 Feb 02 2015
      Vanda Pharmaceuticals to Participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day Jan 29 2015
      Vanda Pharmaceuticals to Participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day Jan 29 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK